We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $697M
1-Year Est. Return 79.73%
This Fund
S&P 500
This Quarter Est. Return
+25.71%
1 Year Est. Return
+79.73%
3 Year Est. Return
+576.62%
5 Year Est. Return
+422.76%
10 Year Est. Return
+2,506.65%
AUM
$336M
AUM Growth
-$103M
Cap. Flow
-$126M
Cap. Flow %
-37.49%
Top 10 Hldgs %
58.57%
Holding
65
New
22
Increased
6
Reduced
11
Closed
14

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$13.4M
2
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12M
3
MDT icon
Medtronic
MDT
+$8.96M
4
TYRA icon
Tyra Biosciences
TYRA
+$8.79M
5
OGN icon
Organon & Co
OGN
+$8.22M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$85.3M
2
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$50.2M
3
IMGN
Immunogen Inc
IMGN
+$19.1M
4
UTHR icon
United Therapeutics
UTHR
+$17.6M
5
CI icon
Cigna
CI
+$13.3M

Sector Composition

Rank Sector Weight
1 Healthcare 85.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
26
Scholar Rock
SRRK
$5.74B
$4.86M 1.45%
+273,720
New +$4.31M
IART icon
27
Integra LifeSciences
IART
$1.38B
$4.86M 1.45%
+137,000
New +$5.48M
OCUL icon
28
Ocular Therapeutix
OCUL
$1.87B
$3.49M 1.04%
383,026
-588,420
-61% -$4.18M
CTMX icon
29
CytomX Therapeutics
CTMX
$723M
$3.48M 1.04%
+1,598,590
New +$2.95M
PCRX icon
30
PUT
Pacira BioSciences
PCRX
$991M
$3.27M 0.97%
+112,000
New +$3.44M
ENTA icon
31
Enanta Pharmaceuticals
ENTA
$384M
$3.09M 0.92%
+177,004
New +$2.34M
STOK icon
32
Stoke Therapeutics
STOK
$2.06B
$3.04M 0.91%
+225,496
New +$1.37M
MODD icon
33
Modular Medical
MODD
$10.9M
$2.85M 0.85%
51,312
+28,334
+123% +$1.52M
RAPT
34
DELISTED
RAPT Therapeutics
RAPT
$2.83M 0.84%
+39,375
New +$5.47M
RVNC
35
DELISTED
Revance Therapeutics, Inc.
RVNC
$2.31M 0.69%
+468,871
New +$2.78M
VTYX
36
DELISTED
Ventyx Biosciences
VTYX
$2.08M 0.62%
+378,000
New +$1.73M
BOLD
37
Boundless Bio
BOLD
$62.9M
$2.04M 0.61%
+143,000
New +$2.04M
APRE icon
38
Aprea Therapeutics
APRE
$7.69M
$1.85M 0.55%
276,603
-3,397
-1% -$21.1K
THRD
39
DELISTED
Third Harmonic Bio
THRD
$1.54M 0.46%
163,363
– –
PRLD icon
40
Prelude Therapeutics
PRLD
$362M
$1.52M 0.45%
320,394
– –
IDYA icon
41
IDEAYA Biosciences
IDYA
$3.47B
$1.45M 0.43%
33,007
– –
IRWD icon
42
Ironwood Pharmaceuticals
IRWD
$683M
$1.3M 0.39%
+149,400
New +$1.81M
FHTX icon
43
Foghorn Therapeutics
FHTX
$287M
$816K 0.24%
121,672
– –
NYXH
44
Nyxoah
NYXH
$141M
$686K 0.2%
50,839
-149,237
-75% -$1.7M
VINC
45
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$516K 0.15%
5,102
– –
NXTC icon
46
NextCure
NXTC
$21.4M
$290K 0.09%
10,833
– –
AVTX icon
47
Avalo Therapeutics
AVTX
$997M
$221K 0.07%
+10,151
New +$54.7K
ASLN
48
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$156K 0.05%
31,769
– –
RCKTW icon
49
Rocket Pharmaceuticals Warrant
RCKTW
$288K
$110K 0.03%
400,000
– –
HUMAW icon
50
Humacyte Inc Warrant
HUMAW
$1.09M
$31K 0.01%
49,998
– –
1
2
3

Similar funds

GUB
Golden Unicorn BVI Road Town $697M AUM 55.92% 1-Year Est. Return
KLI
Kelman-Lazarov Inc Memphis, Tennessee $698M AUM 14.07% 1-Year Est. Return
JA
JLB & Associates Plymouth, Michigan $696M AUM 17.86% 1-Year Est. Return
WIC
Wilkins Investment Counsel Boston, Massachusetts $698M AUM 17.36% 1-Year Est. Return
AAM
Auxier Asset Management Aurora, Oregon $696M AUM 18.07% 1-Year Est. Return
TCM
Tensile Capital Management Larkspur, California $698M AUM 2.4% 1-Year Est. Return
CA
Calton & Associates Tampa, Florida $696M AUM 18.3% 1-Year Est. Return
SAM
Silverback Asset Management Chapel Hill, North Carolina $699M AUM 72.42% 1-Year Est. Return

Sio Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Sio Capital Management held 65 positions worth $336M, down 24% from $439M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Sio Capital Management withdrew a net $126M in Q1 2024, closing 14 positions and reducing 11 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $85.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 88% a quarter earlier.

Against the trend, Sio Capital Management opened a new position in Madrigal Pharmaceuticals worth $13.6M.

  • Sio Capital Management's largest Q1 2024 buy was Madrigal Pharmaceuticals: 51,000 shares worth $13.6M.
  • Sio Capital Management added most to Labcorp in Q1 2024, an estimated $13.4M increase.
  • Sio Capital Management's biggest Q1 2024 reduction was Cigna, cutting an estimated $13.3M.
  • Sio Capital Management fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $85.3M.
  • Sio Capital Management's ten largest holdings make up 59% of its $336M portfolio in Q1 2024.
  • Sio Capital Management opened 22 new positions and closed 14 in Q1 2024.
  • Sio Capital Management's portfolio value fell 24% quarter-over-quarter to $336M.

Based on Sio Capital Management's 13F filing for Q1 2024, filed 15 May 2024.